个人简历

二、教育经历 2001.09-2006.07 武汉大学 临床医学 本科 2012.06-2005.06 武汉大学 生命科学 第二学士学位 2006.9-2011.06 武汉大学 肿瘤学硕博连读 2007.10-2009.10 美国伊利诺伊大学芝加哥分校 联合培养博士研究生 三、工作经历 2011.08-2012.07 中山大学肿瘤防治中心 内科 卫生部住院医生规范化培训； 2012.08-2014.07 中山大学肿瘤防治中心 内科 肿瘤专科医生培训； 2013.05-2013.09 美国加州大学洛杉矶分校进修学习； 2013.12-今中山大学肿瘤防治中心 内科 主治医生。

研究领域

肺癌、鼻咽癌及其它实体肿瘤的化疗及靶向治疗

近期论文

1. Liang W; Wu X; Fang W（方文峰）; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLOS ONE. 2014. 9(2): e85245. 　　2. Fang W（方文峰）, Zhang J, Liang W, Huang Y, Yan Y, Wu X, Hu Z, Ma Y, Zhao H, Zhao Y, Yang Y , Xue C, Zhang J, Zhang L.Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis. 2013. 5(5): 585-92. 　　3. Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, Zhao YY, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Liang WH, Zhao C, Zhang L. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2013 Aug;24(8):2131-6 　　4. Wu X; Liang W; Hou X; Lin Z; Zhao H; Huang Y; Fang W（方文峰）; Zhao Y; Wu J; Yang Y; Xue C; Hu Z; Zhang J;Zhang J; Ma Y; Zhou T; Qin T; Zhang L. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013. 6: 1481-91. 　　5. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, Fang W（方文峰）, Xiong B, Wan Y, Dong C.A Protective Role by Interleukin-17F in Colon Tumorigenesis. PLoS One. 2012. 7(4): e34959. 　　6. Fang W （方文峰）, Goldberg ML, Pohl NM, Bi X, Tong C, Xiong B, Koh TJ, Diamond AM, Yang W. Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis. 2010. 31(8): 1360-6. 　　7. Fang W（方文峰）, Han A, Bi X, Xiong B, Yang W. Tumor inhibition by sodium selenite is associated with activation of c-Jun NH2-terminal kinase 1 and suppression of β-catenin signaling. Int J Cancer. 2010. 127(1): 32-42. 　　8. Bi X, Fang W（方文峰）, Wang LS, Stoner GD, Yang W. Black raspberries inhibit intestinal tumorigenesis in apc1638+/- and Muc2-/- mouse models of colorectal cancer. 　　Cancer Prev Res. 2010. 3(11): 1443-50. 　　9. Benavides MA, Hagen KL, Fang W（方文峰）, Du P, Lin S, Moyer MP, Yang W, Bland KI, Grizzle WE, Bosland MC. Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells. Anticancer Res. 2010. 30(6): 1881-5 　　10. Pohl NM, Tong C, Fang W（方文峰）, Bi X, Li T, Yang W. Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One. 2009. 4(11): e7774. 　　11. Hu D, Bi X, Fang W （方文峰）, Han A, Yang W. GSK3β is involved in JNK2-mediated β-catenin inhibition. PLoS One. 2009. 4(8): e6640. 　　12. Fang W （方文峰）, Fan B, Xiong B. Analysis of pathological risk factors for lymph node metastasis in colorectal cancer. Hepatogastroenterology. 2009. 56(91-92): 663-6. 　　13. Bi X, Zhao Y, Fang W（方文峰）, Yang W. Anticancer activity of Panax notoginseng extract 20(S)-25-OCH3-PPD: Targetting β-catenin signalling. Clin Exp Pharmacol Physiol. 2009. 36(11): 1074-8. 　　14. Hu D, Fang W（方文峰）, Han A, Gallagher L, Davis RJ, Xiong B, Yang W. c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/β-catenin signaling through GSK3β pathway. Carcinogenesis. 2008. 29(12): 2317-24.